Versi Ebrahim

CEO

Adamis Pharmaceuticals Corporation

US, San Diego [HQ]

CIK 1978256

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

8,745

Price per Share :

$0.78

Equivalence :

$6,821.10

Transaction History

A

Form 4

8,745 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 05/25/23
- Footnotes
- Form 4
Footnotes:
#1 On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

#2 Received in exchange for shares of common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.

#3 Received in exchange for shares of common stock of DMK in connection with the Merger. On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.

#4 The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the manager and a member. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interests therein.
A

Form 4

177,194 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 05/25/23
- Footnotes
- Form 4
Footnotes:
#1 On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

#2 Received in exchange for shares of common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.

#3 Received in exchange for shares of common stock of DMK in connection with the Merger. On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.

#4 The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the manager and a member. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interests therein.
C

Form 4

906,394 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 09/15/23
- Footnotes
- Form 4
Footnotes:
#1 On September 15, 2023, Versi Group, LLC converted 729.2 shares of Series E Convertible Preferred Stock ("Series E Preferred") into 729,200 shares of Common Stock, pursuant to the terms of the Series E Preferred. Each share of Series E Preferred is convertible into 1,000 shares of Common Stock at the election of the reporting person, subject to certain beneficial ownership limitations. The Series E Preferred has no expiration date.

#2 The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the manager and a member. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interests therein.